GO:0106380 purine ribonucleotide salvage: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106380 purine ribonucleotide salvage is the biological process that produces purine ribonucleotides from their derivatives without de novo synthesis.
• The pathway is essential for maintaining nucleotide pools in tissues with limited de novo capacity, such as myocardium and brain.
• Key enzymes include HPRT1, APRT, ADA, PNP, and kinases such as ADK and AK, which recycle hypoxanthine, adenine, and adenosine into AMP, GMP, and IMP.
• Purine salvage supports DNA repair and therapy resistance in glioblastoma, making it a potential therapeutic target.
• Defects in salvage enzymes cause human diseases, including Lesch-Nyhan syndrome (HPRT1 deficiency) and severe combined immunodeficiency (ADA deficiency).
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of salvage genes in cancer, neurodegeneration, and metabolic disorders.
Description
Purine ribonucleotide salvage (GO:0106380) is a fundamental metabolic process that recycles purine bases and nucleosides into ribonucleotides, bypassing the energy-expensive de novo synthesis pathway. This process is particularly critical in tissues with high metabolic demand and limited capacity for de novo purine synthesis, such as the heart and brain. The salvage pathway ensures a rapid supply of AMP, GMP, and IMP for RNA synthesis, DNA repair, and cellular energy homeostasis. Researchers study this pathway to understand how cells maintain nucleotide balance under stress, how cancer cells exploit salvage for survival and therapy resistance, and how inherited mutations in salvage enzymes lead to severe human disorders. Targeting purine salvage is emerging as a therapeutic strategy in oncology and neuroprotection.
purine ribonucleotide salvage At A Glance
| GO ID | GO:0106380 |
|---|---|
| GO term | purine ribonucleotide salvage |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process which produces a purine ribonucleotide from derivatives of it, without de novo synthesis. |
| Major function | Recycling of purine bases and nucleosides into AMP, GMP, and IMP to maintain nucleotide pools. |
| Key enzymes | HPRT1, APRT, ADA, PNP, ADK, AK, and others. |
| Tissue relevance | High in myocardium, brain, and rapidly proliferating cells. |
| Disease links | Lesch-Nyhan syndrome, SCID, cancer therapy resistance, neurodegeneration. |
What Is GO:0106380?
According to the Gene Ontology, GO:0106380 purine ribonucleotide salvage is defined as any process which produces a purine ribonucleotide from derivatives of it, without de novo synthesis. In other words, it is the set of biochemical reactions that convert purine bases (e.g., adenine, hypoxanthine, guanine) or purine nucleosides (e.g., adenosine, inosine, guanosine) into purine ribonucleotides (AMP, GMP, IMP) by recycling rather than building the purine ring from simple precursors.
Why Is purine ribonucleotide salvage Important in Cell Biology?
Purine ribonucleotide salvage is vital because it provides a rapid and energy-efficient route to replenish nucleotide pools needed for RNA synthesis, DNA repair, and cellular signaling, especially in tissues with low de novo synthesis capacity. Dysregulation of this pathway contributes to cancer progression, therapy resistance, and inherited metabolic disorders, making it a compelling target for drug discovery and a key area for CRISPR-based functional genomics.
• Maintains nucleotide homeostasis in heart and brain where de novo synthesis is limited.
• Supports DNA repair and resistance to temozolomide in glioblastoma.
• Defects in HPRT1 cause Lesch-Nyhan syndrome, a severe neurological disorder.
• ADA deficiency leads to severe combined immunodeficiency (SCID).
• Provides substrates for NAD+ salvage and cellular energy metabolism.
• Modulates adenosine signaling in cardiovascular and neurological systems.
• Enables rapid recovery of ATP and GTP pools after ischemic injury.
• Is a potential target for anti-cancer and neuroprotective therapies.
• Plays a role in mitochondrial function and oxidative stress responses.
• Influences coenzyme A biosynthesis and acetyl-CoA metabolism.
What Happens During purine ribonucleotide salvage?
Uptake and Phosphoribosylation of Purine Bases
In simple terms: The cell grabs free purine bases and attaches them to a sugar-phosphate, making nucleotides.
The salvage pathway begins with the conversion of purine bases such as hypoxanthine, guanine, and adenine into their corresponding nucleotides. Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) catalyzes the transfer of a phosphoribosyl group from PRPP to hypoxanthine and guanine, yielding IMP and GMP, respectively. Adenine phosphoribosyltransferase (APRT) performs the analogous reaction for adenine to produce AMP. These reactions are highly conserved and represent the primary salvage route in most mammalian tissues.
Phosphorylation of Purine Nucleosides
In simple terms: The cell adds phosphate groups to purine nucleosides like adenosine to turn them into nucleotides.
Purine nucleosides such as adenosine, inosine, and guanosine can be directly phosphorylated by nucleoside kinases. Adenosine kinase (ADK) phosphorylates adenosine to AMP, while inosine and guanosine are phosphorylated by other kinases. This route is particularly important in the heart and brain, where adenosine levels fluctuate rapidly and require efficient conversion to AMP for energy balance.
Deamination and Interconversion
In simple terms: The cell modifies purine nucleosides by removing amine groups to feed them back into the salvage pool.
Adenosine deaminase (ADA) converts adenosine to inosine, and purine nucleoside phosphorylase (PNP) converts inosine to hypoxanthine and guanosine to guanine. These deamination and phosphorolysis reactions allow the recycling of purine rings from one nucleotide to another, maintaining balanced pools of AMP, GMP, and IMP.
Nucleotide Interconversion and Energy Charge
In simple terms: The cell converts one nucleotide into another to keep energy and building blocks balanced.
Salvaged IMP can be converted to AMP and GMP through the sequential actions of adenylosuccinate synthetase and lyase, or IMP dehydrogenase and GMP synthetase, respectively. These interconversion reactions ensure that the cell can adjust the relative amounts of adenine and guanine nucleotides according to metabolic demand, particularly during stress and recovery.
Integration with NAD+ and CoA Metabolism
In simple terms: Salvage products feed into other essential metabolic pathways like NAD+ and coenzyme A synthesis.
Purine salvage is interconnected with NAD+ salvage and coenzyme A biosynthesis. For example, nicotinamide mononucleotide adenylyltransferase (NMNAT1) uses ATP (a purine nucleotide) to generate NAD+, linking purine salvage to cellular redox and energy metabolism. Similarly, coenzyme A biosynthesis requires ATP and GTP, highlighting the dependence of these pathways on purine salvage.
Key Genes Involved in GO:0106380 purine ribonucleotide salvage
The following genes encode enzymes and transporters that directly participate in or regulate purine ribonucleotide salvage.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HPRT1 | Converts hypoxanthine and guanine to IMP and GMP | Mutations cause Lesch-Nyhan syndrome; target for cancer and neurobiology |
| APRT | Converts adenine to AMP | Deficiency causes 2,8-dihydroxyadenine urolithiasis; model for purine salvage |
| ADA | Deaminates adenosine to inosine | Deficiency causes SCID; target for enzyme replacement therapy |
| PNP | Phosphorolyzes inosine and guanosine to bases | Deficiency causes T-cell immunodeficiency; drug target |
| ADK | Phosphorylates adenosine to AMP | Regulates adenosine signaling in brain and heart |
| AK | Phosphorylates adenosine to AMP | Maintains energy charge in muscle and heart |
| IMPDH1 | Converts IMP to XMP in GMP synthesis | Target for immunosuppression and cancer therapy |
| IMPDH2 | Converts IMP to XMP in GMP synthesis | Overexpressed in tumors; potential drug target |
| GMPS | Converts XMP to GMP | Required for GMP salvage; linked to cell proliferation |
| ADSS1 | Converts IMP to adenylosuccinate | Muscle-specific isoform; mutations cause myopathy |
| ADSL | Cleaves adenylosuccinate to AMP | Deficiency causes adenylosuccinate lyase deficiency |
| NT5C2 | Dephosphorylates purine nucleotides to nucleosides | Mutations in leukemia; regulates salvage flux |
| SLC29A1 | Equilibrative nucleoside transporter 1 | Uptake of nucleosides for salvage; drug transport |
| SLC29A2 | Equilibrative nucleoside transporter 2 | Uptake of nucleosides; tissue-specific expression |
| NMNAT1 | Synthesizes NAD+ from NMN and ATP | Links purine salvage to NAD+ metabolism; neuroprotection |
| PPAT | Catalyzes first step of CoA biosynthesis using ATP | Connects purine salvage to CoA and acetyl-CoA |
| RRM1 | Ribonucleotide reductase subunit; converts NDPs to dNDPs | Balances ribonucleotide pools; target in cancer |
| RRM2 | Ribonucleotide reductase subunit; converts NDPs to dNDPs | Overexpressed in glioblastoma; therapy resistance |
How Is purine ribonucleotide salvage Regulated?
Purine ribonucleotide salvage is regulated at multiple levels. Enzyme expression is controlled by transcription factors responsive to nucleotide availability, such as the purine repressor in bacteria and mTOR signaling in mammals. Allosteric regulation by nucleotides (e.g., AMP, GMP, ATP) modulates enzyme activity to maintain balanced pools. In cancer, oncogenic signaling can upregulate salvage enzymes to support rapid proliferation and DNA repair. Additionally, adenosine signaling through receptors influences salvage flux in cardiovascular and neurological tissues. Post-translational modifications, such as lactylation of NMNAT1, can enhance NAD+ salvage under metabolic stress.
purine ribonucleotide salvage and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HPRT1 | Lesch-Nyhan syndrome; hyperuricemia; neurological dysfunction | HPRT1 knockout iPSCs and neurons; point mutation knock-in mice |
| ADA | Severe combined immunodeficiency (SCID) | ADA knockout mice; knock-in of patient mutations; overexpression for rescue |
| IMPDH2 | Cancer proliferation; immunosuppression | IMPDH2 knockout and overexpression in glioblastoma cell lines |
| ADK | Epilepsy; cardiovascular disease; adenosine signaling | ADK knockout mice; brain-specific overexpression |
| NMNAT1 | Neurodegeneration; NAD+ metabolism; cancer survival | NMNAT1 knockout and lactylation-mimic knock-in in pancreatic cancer cells |
Cancer and Therapy Resistance
Purine salvage supports DNA repair and resistance to temozolomide in glioblastoma. Zhou et al. (2020) demonstrated that purine metabolism regulates DNA repair and therapy resistance, and targeting salvage enzymes sensitizes glioblastoma cells to chemotherapy. Overexpression of IMPDH2 and RRM2 is associated with poor prognosis, making salvage a therapeutic vulnerability.
Inherited Metabolic Disorders
Deficiencies in salvage enzymes cause severe human diseases. HPRT1 deficiency leads to Lesch-Nyhan syndrome, characterized by hyperuricemia and neurological dysfunction. ADA deficiency results in severe combined immunodeficiency (SCID) due to accumulation of toxic deoxyadenosine. PNP deficiency causes T-cell immunodeficiency. These disorders highlight the non-redundant roles of salvage enzymes in human health.
Neurodegeneration and Brain Injury
The mammalian purine salvage pathway is an exploitable route for cerebral bioenergetic support after brain injury. Enhancing salvage can restore ATP levels and reduce neuronal death in ischemia. Adenosine metabolism and signaling are critical in the heart and brain, where ADK and AK modulate adenosine responses. Dysregulation of salvage contributes to oxidative damage and mitochondrial dysfunction in aging.
Metabolic and Mitochondrial Disorders
Purine salvage is interconnected with NAD+ and coenzyme A metabolism. NMNAT1 lactylation sustains nuclear NAD+ salvage and promotes survival of pancreatic adenocarcinoma cells under glucose deprivation. Coenzyme A biosynthesis, which requires ATP, is linked to purine pools and regulates acetyl-CoA for energy production. Ovarian aging is characterized by oxidative damage and mitochondrial dysfunction, where nucleotide salvage may play a protective role.
From purine ribonucleotide salvage-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does HPRT1 loss impair nucleotide salvage and cause neuronal dysfunction? | HPRT1 knockout iPSC-derived neurons; point mutation knock-in mice |
| Can ADA deficiency be rescued by overexpression of wild-type ADA? | ADA knockout cell lines; lentiviral overexpression of ADA |
| Does IMPDH2 overexpression drive temozolomide resistance? | IMPDH2 overexpression in glioblastoma cells; knockout validation |
| What is the role of ADK in adenosine signaling in the brain? | ADK knockout mice; tagged knock-in for localization |
| Does NMNAT1 lactylation enhance NAD+ salvage under glucose deprivation? | NMNAT1 lactylation-mimic knock-in in pancreatic cancer cells |
| Can purine salvage support bioenergetics after brain injury? | Knock-in of salvage enzymes in mouse models of ischemia |
How to Study the purine ribonucleotide salvage Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of purine nucleotides, nucleosides, and bases | Quantify salvage flux in cells and tissues |
| Stable isotope tracing | Incorporation of labeled precursors into nucleotides | Measure pathway activity and interconversion |
| RNA-seq | Expression of salvage genes | Identify transcriptional regulation and disease signatures |
| CRISPR screen + sequencing | Genes required for salvage-dependent growth | Discover therapeutic targets in cancer |
| Proteomics | Protein abundance and modifications | Detect lactylation, phosphorylation of salvage enzymes |
| NAD+ biosensor imaging | Real-time NAD+ levels | Monitor NAD+ salvage in live cells |
| Comet assay | DNA repair capacity | Link salvage to DNA repair and therapy resistance |
| Cell proliferation assay | Growth dependence on salvage | Evaluate drug sensitivity and gene knockout effects |
Metabolomics and Flux Analysis
Liquid chromatography-mass spectrometry (LC-MS) based metabolomics quantifies purine nucleotides, nucleosides, and bases to assess salvage flux. Stable isotope tracing with 13C/15N-labeled precursors (e.g., hypoxanthine, adenosine) reveals pathway activity and interconversion rates. These methods are essential for validating CRISPR models and drug effects.
Genomic and Transcriptomic Profiling
RNA-seq and single-cell RNA-seq measure expression of salvage genes (HPRT1, APRT, ADA, PNP, ADK, etc.) across tissues and disease states. CRISPR screens coupled with RNA-seq identify genes that modulate salvage pathway dependencies, particularly in cancer. Bioinformatics analysis of public datasets (e.g., TCGA) links salvage gene expression to patient outcomes.
Proteomics and Post-Translational Modifications
Mass spectrometry-based proteomics detects protein levels and post-translational modifications of salvage enzymes, such as lactylation of NMNAT1. Phosphoproteomics can reveal signaling events that regulate enzyme activity. These approaches help dissect how salvage is rewired in disease.
Imaging and Functional Assays
Fluorescent biosensors for ATP, GTP, and NAD+ enable real-time monitoring of salvage activity in live cells. Immunofluorescence and live-cell imaging localize salvage enzymes to subcellular compartments. Functional assays such as cell proliferation, DNA repair (comet assay), and drug sensitivity link salvage to cellular phenotypes.
How CRISPR Can Be Used to Study GO:0106380 purine ribonucleotide salvage
Knockout
CRISPR knockout of salvage genes (e.g., HPRT1, APRT, ADA, PNP, ADK) creates isogenic cell lines to study loss-of-function phenotypes. These models reveal essential roles in nucleotide homeostasis, DNA repair, and drug resistance. Knockout of IMPDH2 in glioblastoma cells reduces proliferation and sensitizes to temozolomide.
Point Mutation
Point mutation knock-in models recapitulate patient-specific mutations, such as HPRT1 mutations in Lesch-Nyhan syndrome or ADA mutations in SCID. These models enable precise dissection of enzyme activity and substrate specificity, and are valuable for testing targeted therapies.
Knock-in
Knock-in of tagged salvage enzymes (e.g., GFP- or HA-tagged HPRT1, ADK) allows live-cell imaging and proteomic analysis of localization and interactions. Knock-in of lactylation-mimic mutations in NMNAT1 can test the functional impact of post-translational modifications.
Overexpression
Overexpression of salvage enzymes (e.g., IMPDH2, RRM2, NMNAT1) via lentiviral or CRISPR activation models drives pathway flux and can induce therapy resistance or metabolic rewiring. These models are useful for gain-of-function studies and drug screening.
How EDITGENE Supports purine ribonucleotide salvage Research
Researchers studying purine ribonucleotide salvage-related genes often need to determine whether a candidate gene is causally involved in nucleotide homeostasis, disease progression, or therapy response. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for purine ribonucleotide salvage research.
Frequently Asked Questions About purine ribonucleotide salvage
What is purine ribonucleotide salvage?
Purine ribonucleotide salvage (GO:0106380) is the biological process that produces purine ribonucleotides from their derivatives without de novo synthesis, recycling bases and nucleosides into AMP, GMP, and IMP.
What genes are involved in purine ribonucleotide salvage?
Key genes include HPRT1, APRT, ADA, PNP, ADK, AK, IMPDH1/2, GMPS, ADSS1, ADSL, NT5C2, SLC29A1/2, NMNAT1, PPAT, RRM1, and RRM2.
Why is purine salvage important in cancer?
Purine salvage supports DNA repair and therapy resistance in glioblastoma and other cancers, making it a therapeutic target.
What diseases are linked to purine salvage defects?
Defects cause Lesch-Nyhan syndrome (HPRT1), severe combined immunodeficiency (ADA), PNP deficiency, and are implicated in neurodegeneration and mitochondrial disorders.
How is purine ribonucleotide salvage regulated?
It is regulated by allosteric feedback, transcriptional control, mTOR signaling, and post-translational modifications such as lactylation.
What methods are used to study purine salvage?
LC-MS metabolomics, stable isotope tracing, RNA-seq, CRISPR screens, proteomics, and biosensor imaging are commonly used.
Can CRISPR be used to model purine salvage disorders?
Yes, CRISPR knockout, point mutation knock-in, and overexpression models recapitulate patient mutations and enable functional studies.
What is the role of HPRT1 in purine salvage?
HPRT1 converts hypoxanthine and guanine to IMP and GMP; its deficiency causes Lesch-Nyhan syndrome.
How does adenosine metabolism relate to purine salvage?
Adenosine kinase and adenosine deaminase regulate adenosine levels and its conversion to AMP or inosine, linking salvage to cardiovascular and neurological function.
What is the connection between purine salvage and NAD+ metabolism?
NMNAT1 uses ATP to synthesize NAD+, linking purine salvage to NAD+ salvage and cellular energy metabolism.
Conclusion
Purine ribonucleotide salvage (GO:0106380) is a central metabolic process that ensures rapid nucleotide supply for DNA repair, RNA synthesis, and energy homeostasis. Its dysregulation contributes to cancer, immunodeficiency, and neurodegeneration, making it a high-value target for therapeutic intervention. CRISPR-based models are indispensable for dissecting the causal roles of salvage genes and for developing precision therapies. EDITGENE offers comprehensive services to accelerate this research.
References
- 1. Smits MAJ et al.. 2023. Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction.. Hum Reprod 38(11):2208-2220 PMID: 37671592
- 2. Barritt SA et al.. 2024. Coenzyme A biosynthesis: mechanisms of regulation, function and disease.. Nat Metab 6(6):1008-1023 PMID: 38871981
- 4. Manfredi JP et al.. 1985. Purine salvage pathways in myocardium.. Annu Rev Physiol 47:691-705 PMID: 2986542
- 5. Zhou W et al.. 2020. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma.. Nat Commun 11(1):3811 PMID: 32732914
- 6. Huang H et al.. 2024. Lactate enhances NMNAT1 lactylation to sustain nuclear NAD(+) salvage pathway and promote survival of pancreatic adenocarcinoma cells under glucose-deprived conditions.. Cancer Lett 588:216806 PMID: 38467179
- 7. Headrick JP et al.. 2001. 5'-Adenosine monophosphate and adenosine metabolism, and adenosine responses in mouse, rat and guinea pig heart.. Comp Biochem Physiol A Mol Integr Physiol 130(4):615-31 PMID: 11691599
- 8. Gessner P et al.. 2023. The mammalian purine salvage pathway as an exploitable route for cerebral bioenergetic support after brain injury.. Neuropharmacology 224:109370 PMID: 36493858
